225 related articles for article (PubMed ID: 7640206)
1. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.
Lohmeyer M; Workman P
Br J Cancer; 1995 Aug; 72(2):277-86. PubMed ID: 7640206
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
Dive C; Watson JV; Workman P
Cancer Res; 1991 Feb; 51(3):799-806. PubMed ID: 1988120
[TBL] [Abstract][Full Text] [Related]
3. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe.
Lohmeyer M; Workman P
Biochem Pharmacol; 1993 Jan; 45(1):77-86. PubMed ID: 8424826
[TBL] [Abstract][Full Text] [Related]
4. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action.
Lohmeyer M; Workman P
Biochem Pharmacol; 1992 Aug; 44(4):819-23. PubMed ID: 1510728
[TBL] [Abstract][Full Text] [Related]
5. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
Workman P; Donaldson J; Lohmeyer M
Biochem Pharmacol; 1991 Jan; 41(2):319-22. PubMed ID: 1989642
[No Abstract] [Full Text] [Related]
6. Tumor cell kinetics following antineoplastic ether phospholipid treatment.
Principe P; Sidoti C; Braquet P
Cancer Res; 1992 May; 52(9):2509-15. PubMed ID: 1568220
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues.
Berggren MI; Gallegos A; Dressler LA; Modest EJ; Powis G
Cancer Res; 1993 Sep; 53(18):4297-302. PubMed ID: 8395981
[TBL] [Abstract][Full Text] [Related]
9. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
Bazill GW; Dexter TM
Cancer Res; 1990 Dec; 50(23):7505-12. PubMed ID: 2253199
[TBL] [Abstract][Full Text] [Related]
10. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Chabot MC; Wykle RL; Modest EJ; Daniel LW
Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
12. The effect of ether lipid 1-O-octadecyl-2-O-methoxy-rac-glycero-3-phosphocholine and its analogues platelet activating factor and carbamyl-platelet activating factor on the biosynthesis of interleukin-6 in human thymic epithelial cells cultivated in vitro.
Cardile V; Mascarucci P; De Simoni MG; Jiang X; Bindoni M
Cytokine; 1996 Sep; 8(9):698-701. PubMed ID: 8932980
[TBL] [Abstract][Full Text] [Related]
13. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Small GW; Strum JC; Daniel LW
Lipids; 1997 Jul; 32(7):715-23. PubMed ID: 9252959
[TBL] [Abstract][Full Text] [Related]
14. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of synthetic alkylphospholipids with or without PAF activity.
Kudo I; Nojima S; Chang HW; Yanoshita R; Hayashi H; Kondo E; Nomura H; Inoue K
Lipids; 1987 Nov; 22(11):862-7. PubMed ID: 3444379
[TBL] [Abstract][Full Text] [Related]
16. Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines.
Civoli F; Daniel LW
Cancer Chemother Pharmacol; 1998; 42(4):319-26. PubMed ID: 9744778
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
Powis G; Seewald MJ; Gratas C; Melder D; Riebow J; Modest EJ
Cancer Res; 1992 May; 52(10):2835-40. PubMed ID: 1316230
[TBL] [Abstract][Full Text] [Related]
18. Relationship of cell survival, drug dose, and drug uptake after 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine treatment.
Fujiwara K; Daniel LW; Modest EJ; Wallen CA
Cancer Chemother Pharmacol; 1994; 34(6):472-6. PubMed ID: 7923557
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action.
Diomede L; Colotta F; Piovani B; Re F; Modest EJ; Salmona M
Int J Cancer; 1993 Jan; 53(1):124-30. PubMed ID: 8416196
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of HL-60 cells distinguishes between cytostatic and cytotoxic effects of the alkylphospholipid ET-18-OCH3.
Civoli F; Pauig SB; Daniel LW
Cancer Chemother Pharmacol; 1996; 38(3):269-72. PubMed ID: 8646802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
